New prognostic biomarkers in multiple myeloma
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2016, Vol 70, Issue
Abstract
Multiple myeloma is a malignant neoplastic disease, characterized by uncontrolled proliferation and accumulation of plasma cells in the bone marrow, which is usually connected with production of a monoclonal protein. It is the second most common hematologic malignancy. It constitutes approximately 1% of all cancers and 10% of hematological malignancies. Despite the huge progress that has been made in the treatment of multiple myeloma in the past 30 years including the introduction of new immunomodulatory drugs and proteasome inhibitors, it is still an incurable disease. According to current data, the five-year survival rate is 45%. Multiple myeloma is a very heterogeneous disease with a very diverse clinical course, which is expressed by differences in effectiveness of therapeutic strategies and ability to develop chemoresistance. This diversity implies the need to define risk stratification factors that would help to create personalized and optimized therapy and thereby improve treatment outcomes. Prognostic markers that aim to objectively evaluate the risk of a poor outcome, relapse and the patient’s overall outcome are useful for this purpose. The existing, widely used prognostic classifications, such as the Salmon-Durie classification or ISS, do not allow for individualization of treatment. As a result of the development of diagnostic techniques, especially cytogenetics and molecular biology, we were able to discover a lot of new, more sensitive and specific prognostic factors. The paper presents recent reports on the role of molecular, cytogenetic and biochemical alterations in pathogenesis and prognosis of the disease.
Authors and Affiliations
Aneta Szudy-Szczyrek, Michał Szczyrek, Maria Soroka-Wojtaszko, Marek Hus
Keywords
Related Articles
- EP ID EP206126
- DOI -
- Views 142
- Downloads 0
Genes and childhood leukemia
Leukemia is a heterogeneous hematologic malignancy originating from a multipotent hematopoietic stem cell. It ranks among the commonest cancers in childhood and is characterized by excessive proliferation and differentia...
Przeciwciała monoklonalne w terapii celowanej
Terapia celowana jest nową metodą terapeutyczną polegającą na hamowaniu określonych szlaków molekularnych. Główną rolę w nowoczesnej terapii odgrywają przeciwciała monoklonalne, zaliczane do grupy leków biologicznych. Wa...
Receptory aktywowane przez proteazy – biologia i rola w nowotworach złośliwych
Zaburzenia krzepnięcia krwi nie tylko towarzyszą chorobie nowotworowej, ale wpływają również na jej rozwój. Komórki nowotworowe są zdolne do wytwarzania zarówno wielu czynników prozakrzepowych, jak i mechanizmów umożliwi...
The role of Th1, Th17, and Treg cells in the pathogenesis of rheumatoid arthritis including anti-inflammatory action of Th1 cytokines
Dysregulation in the immune system plays an important role in the pathogenesis of rheumatoid arthritis (RA). The persistent nature of arthritis strengthens the suggestion of immune dysfunction, consisting in predominan...
The CRISPR-Cas system – from bacterial immunity to genome engineering
Precise and efficient genome modifications present a great value in attempts to comprehend the roles of particular genes and other genetic elements in biological processes as well as in various pathologies. In recent yea...